Parkinson’s disease is a chronic disease that requires long-term treatment. Among the medications used to treat Parkinson’s disease, compound dopa preparations such as Methyldopa and Restnin have the best therapeutic effect; however, many patients are afraid to take such medications for fear that adverse reactions such as motor fluctuations and anisotropy may occur after taking compound dopa preparations. After scientific research, it has been found that the dosage of compound dopa preparations can be controlled within a reasonable range to effectively improve the symptoms without significantly increasing the risk of adverse reactions. In the past, the dosage of compound dopa was mainly determined based on experience or patients’ feelings, which may result in a significant under-dosage leading to insufficient efficacy, or a relatively high dosage in order to pursue significant improvement. Based on the findings of our research team, a standardized levodopa efficacy assessment by physicians is expected to result in the screening of drug doses that are both effective in improving symptoms and as low as possible. This is simple, possible, inexpensive, and requires only one to several days of hospitalization (generally no more than five days), and it may be possible to assess whether a patient’s diagnosis is accurate because of a definitive improvement in symptoms after taking compounded levodopa, as well as to accurately assess the appropriate dosage and number of doses to be taken.